Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical ...

By Arjan Singh Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, ...

Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

503B compounders require special attention to maintain cGMP and regulation compliance. Examine the process for designing and managing new facilities for sterile and parenteral injectable manufacturing ...

Three years ago, AbbVie decided to stop talking about using digital technologies in clinical trials and start actually using them. The company then began deploying wearables in three clinical trials.

As the use of AI increases and expands to new functional areas within biopharmaceutical companies, leaders must understand the risks and mitigate the impact of hallucinations in AI model outputs.